COMPANY PROFILE

Mido Bio

Explore full profile

The first molecular imaging and pharmaceutical R&D outsourcing (MI-CRO) enterprise in China

Nanjing City, ChinaFounded 2012Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Mido Bio

MITRO, established in 2012 and headquartered in Jiangning District, Nanjing City, operates in the radiopharmaceutical industry, providing Contract Research, Development, and Manufacturing Organization (CRDMO) services. With offices in China, the United States, and the United Kingdom, and a workforce of over 200 employees, MITRO serves global pharmaceutical and biomedical clients. The company focuses on radioisotope labeled molecular imaging, facilitating the development of innovative drugs. MITRO's business model includes offering preclinical and clinical studies, R&D services, and imaging services. The company generates revenue through service contracts with over 700 global sponsors and has achieved 20 clinical approvals.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2012
Headquarters: Nanjing City, China
Employees: 6
Open positions: None listed
Dealroom signal: 22.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Mar 2024	$52M	$209M	Yantai Guofeng Investment Holding Group · SDIC Fund Management · State Development & Investment Corporation (SDIC)	↗
ACQUISITIONOther financing	Apr 2012	$0	—	Yantai Dongcheng Pharmaceutical	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Mido Bio website traffic

Latest recorded traffic for Mido Bio is 2.2K monthly website visits, down 37.1% over the last three months.

Latest monthly visits2.2K 3-month web change-37.1%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISolid IOMaking immunotherapies accessible at scale.	Helsinki, Finland	Operational	13	$880K	$3.5M
LTLys TherapeuticsInnovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis	Caen, France	Operational
INInnoSkelA pioneering biotechnology company developing therapies for rare skeletal diseases	Valbonne, France	Operational
CACarvolixThe new generation of minimally invasive implants to treat diseases of the heart, aorta, and urinary incontinence	Paris, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
QFQfluidicsDevelops low shear technologies based on its patented technology of liquid tube to offer innovative equipment dedicated to the biotechnology and biopharmaceutical production	Strasbourg, France	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational